Earnings call transcript: Nolato Q1 2026 reveals earnings miss, stock slides

Nolato AB’s Q1 2026 results missed expectations, with EPS of $0.67 versus $0.712 consensus and revenue of $2.36 billion versus $2.37 billion forecast, while the stock fell 17.72% from the prior close. EBITDA margin held at 11%, cash flow from operations rose 67% to SEK 225 million, but management warned that 5%-10% raw material inflation and currency headwinds will pressure margins into Q2 and Q3. Capex guidance remains SEK 650 million-SEK 700 million for 2026, with growth tied to Medical Solutions and expansion in Hungary and Malaysia.

Analysis

The selloff looks less like a simple miss and more like the market repricing two embedded earnings downgrades: FX and input-cost lag. Because management says the cost pass-through lags by roughly one quarter and the raw-material shock is still in front of them, the near-term margin compression window likely extends through Q2 and bleeds into Q3 before pricing catches up. That makes this a timing trade, not a structural earnings collapse, but the market is usually willing to punish “transitory” margin pressure when it overlaps with a de-rating from near-52-week-low levels.

The second-order issue is mix. The higher-growth medical programs are still in ramp, but ramps are capital- and quality-cost intensive before they become margin accretive, so the best growth line item is currently a drag on reported profitability. Meanwhile, engineered materials growth is partly volume-led and partly price/mix, which means it is more exposed to raw-material inflation than headline growth suggests; if customers resist price resets, the margin bridge can deteriorate faster than revenue does.

The contrarian setup is that the market may be over-penalizing the company for a cash-flow-positive quarter. Strong operating cash generation and low leverage give management room to fund capacity buildout without equity dilution, and that matters when competitors facing the same input-cost shock may have to slow capex or sacrifice price discipline. If Q2 confirms that pricing actions are flowing through and the medical ramp stays on schedule, this could become a classic “bad quarter, better setup” situation over the next 2-3 quarters.

Key Decisions for Investors

• Short term: buy downside protection into Q2 results rather than outright shorting — e.g., SEB 3-6 month put spread if liquidity allows, targeting further de-rating while the FX/input-cost lag is still unresolved; risk/reward is favorable because the next catalyst window is near-term and asymmetric.
• Medium term: initiate a staggered long only after evidence of pass-through, not on the current dip — use a 30-40% starter position now and add on confirmation of Q2 gross margin stabilization; upside is a re-rating toward prior valuation if the market accepts the margin trough thesis.
• Pair trade: long Nolato vs short a more commodity-sensitive manufacturing/medical supplier with weaker balance sheet and less pricing power; the thesis is that Nolato’s low leverage and pass-through history should outperform peers during an input-cost shock.
• For event-driven accounts: sell premium via covered calls or call spreads against a core long position over the next 1-2 quarters, since implied volatility likely remains elevated until management proves Q3 normalization.
• Set a stop/review trigger if medical ramp volumes slip again in Q2: that would convert this from temporary margin compression into a credibility problem, warranting a full exit rather than a dip buy.